Comment from Arnold Ventures

Summary: Arnold Ventures, a philanthropy focused on evidence-based policy, supports the Commissioner’s National Priority Voucher (CNPV) Pilot Program but urges the FDA to implement strict transparency, accountability, and safety measures. They specifically call for clear evaluation criteria, robust post-market evidence collection, and adequate staffing resources to ensure the program does not compromise the agency's safety and efficacy standards.